Alumis Inc. Common Stock
ALMSAlumis Inc. (ALMS) is a biotechnology company focused on developing innovative therapies and solutions primarily within the healthcare and life sciences sectors. The company emphasizes advancing scientific research and technology to address unmet needs in medical treatments, often concentrating on areas such as antibody engineering and advanced therapeutics.
Company News
Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.
Alumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.
Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.
